Publications
Braunack-Mayer L, Malinga J, Masserey T, Nekkab N, Sen S, Schellenberg D, Tchouatieu A.M, Kelly S.L, Penny M.A. Design and selection of drug properties to increase the public health impact of next-generation seasonal malaria chemoprevention: a modelling study. Lancet Glob Health. 2024;12(3):e478-e490. DOI: 10.1016/s2214-109x(23)00550-8
Price D.J, Nekkab N, Monteiro W.M, Villela D.A.M, Simpson J.A, Lacerda M.V.G, White M.T, Devine A. Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: a cost-effectiveness analysis using a transmission model. PLoS Med. 2024;21(1):e1004255. DOI: 10.1371/journal.pmed.1004255
Nekkab N, Malinga J, Braunack-Mayer L, Kelly S.L, Miller R.S, Penny M.A. Modelling to inform next-generation medical interventions for malaria prevention and treatment. Commun Med (Lond). 2023;3:41. DOI: 10.1038/s43856-023-00274-0
Nekkab N, Obadia T, Monteiro W.M, Lacerda M.V.G, White M, Mueller I. Accelerating towards P. vivax elimination with a novel serological test-and-treat strategy: a modelling case study in Brazil. Lancet Reg Health Am. 2023;22:100511. DOI: 10.1016/j.lana.2023.100511
Nekkab N, Penny M.A. Accelerated development of malaria monoclonal antibodies. Cell Rep Med. 2022;3(10):100786. DOI: 10.1016/j.xcrm.2022.100786
Obadia T, Nekkab N, Robinson L.J, Drakeley C, Mueller I, White M.T. Developing sero-diagnostic tests to facilitate Plasmodium vivax serological test-and-treat approaches: modeling the balance between public health impact and overtreatment. BMC Med. 2022;20:98. DOI: 10.1186/s12916-022-02285-5